Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived

Published:2009-11 Issue:5 Volume:83 Page:449-454
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Corso Alessandro,Varettoni Marzia,Mangiacavalli Silvia,Zappasodi Patrizia,Pica Gian Matteo,Algarotti Alessandra,Pascutto Cristiana,Lazzarino Mario

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2009.01295.x/fullpdf

Reference19 articles.

1. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed MM: an Eastern Cooperative Oncology Group study;Gertz;Am J Clin Oncol,1995

2. Treatment approaches for relapsing and refractory MM;Bladé;Acta Oncol,2000

3. Clinical course of patients with relapsed MM;Kumar;Mayo Clin Proc,2004

4. A phase 2 study of Bortezomib in relapsed, refractory myeloma;Richardson;N Engl J Med,2003

5. A phase 2 study of two doses of Bortezomib in relapsed or refractory myeloma;Jagannath;Br J Haematol,2004

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial;The Lancet Haematology;2016-11

2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study;The Lancet Oncology;2016-01

3. Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma;Anti-Cancer Drugs;2015-11

4. The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit;American Journal of Hematology;2015-02-27

5. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma;Haematologica;2014-09-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3